The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Data update in advanced stage NSCLC
Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland discusses the ongoing clinical trials investigating advanced stage non-small cell lung cancer (NSCLC) at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. Dr Peters provides insight into the design of the ETOP 6-14 NICOLAS trial (NCT02434081), investigating the addition of the anti-PD-1 agent, nivolumab, to standard first-line chemotherapy and radiotherapy. Making comparisons to the PACIFIC (NCT02125461) trial, evaluating the anti-PD-L1 agent, durvalumab following concurrent chemoradiation therapy, Dr Peters shares the latest results from both trials.
